Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTESS: Alfuzosin for AUR Prevention in BPH
NCT00029822Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2001
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in benign prostatic hyperplasia (BPH) comparing Alfuzosin with Placebo (2 arms). Primary endpoint: Occurrence of first episode of Acute Urinary Retention at 2 years. Started May 2001; status: completed.
02
Drugs
alfuzosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT00029822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00029822.